Business Description
Bioventus Inc
NAICS : 339112
SIC : 3845
ISIN : US09075A1088
Share Class Description:
FRA:4B8: Class ATotal Employee Number:
940Description
Bioventus Inc is a medical device company focused on developing and commercializing products to relieve pain and address musculoskeletal conditions. The company operates through two reporting segments, U.S. and International, and its product portfolio is organized into three main business areas: Pain Treatments, Surgical Solutions, and Restorative Therapies, offering products such as hyaluronic acid injections for osteoarthritis, peripheral nerve stimulation devices, bone graft substitutes, and ultrasound-based fracture healing therapies.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.12 | |||||
Equity-to-Asset | 0.34 | |||||
Debt-to-Equity | 1.09 | |||||
Debt-to-EBITDA | 2.39 | |||||
Interest Coverage | 3.05 | |||||
Piotroski F-Score | 8/9 | |||||
Altman Z-Score | 2.52 | |||||
Beneish M-Score | -2.66 | |||||
WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -0.4 | |||||
3-Year EPS without NRI Growth Rate | 58.7 | |||||
3-Year Book Growth Rate | -19.4 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 16.3 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 6.46 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.69 | |||||
Quick Ratio | 1.17 | |||||
Cash Ratio | 0.19 | |||||
Days Inventory | 175.28 | |||||
Days Sales Outstanding | 81.55 | |||||
Days Payable | 42.45 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -2.6 | |||||
Shareholder Yield % | 5.96 |
Profitability Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 68.65 | |||||
Operating Margin % | 10.41 | |||||
Net Margin % | 9.36 | |||||
EBITDA Margin % | 17.83 | |||||
FCF Margin % | 16.16 | |||||
OCF Margin % | 16.6 | |||||
ROE % | 29.32 | |||||
ROA % | 7.97 | |||||
ROIC % | 11.39 | |||||
3-Year ROIIC % | -10.76 | |||||
ROC (Joel Greenblatt) % | 50.38 | |||||
ROCE % | 11.22 | |||||
Years of Profitability over Past 10-Year | 4 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 18.34 | |||||
Forward PE Ratio | 19.18 | |||||
PE Ratio without NRI | 14.04 | |||||
Price-to-Owner-Earnings | 14.76 | |||||
PS Ratio | 1.69 | |||||
PB Ratio | 4.38 | |||||
Price-to-Free-Cash-Flow | 10.42 | |||||
Price-to-Operating-Cash-Flow | 10.13 | |||||
EV-to-EBIT | 24.88 | |||||
EV-to-EBITDA | 14.03 | |||||
EV-to-Revenue | 2.5 | |||||
EV-to-Forward-Revenue | 2.33 | |||||
EV-to-FCF | 15.44 | |||||
Price-to-GF-Value | 1.83 | |||||
Price-to-Projected-FCF | 2.3 | |||||
Earnings Yield (Greenblatt) % | 4.02 | |||||
FCF Yield % | 7.94 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Bioventus Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 500.22 | ||
| EPS (TTM) (€) | 0.665 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | - | ||
| 14-Day RSI | 63.39 | ||
| 14-Day ATR (€) | 0.443613 | ||
| 20-Day SMA (€) | 10.8425 | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range (€) | 8.06 - 13.1 | ||
| Shares Outstanding (Mil) | 84.09 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 8 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Bioventus Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Bioventus Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-04 08:30 | In 87 days | ||
| Third quarter earnings results for 2026 | 2026-11-04 | In 86 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-05 08:30 | 11.80 (+0.00%) | ||
| Second quarter earnings results for 2026 | 2026-08-05 | 11.80 (+0.00%) | ||
| Goldman Sachs Global Healthcare Conference | 2026-06-08 16:00 | -- | ||
| General meeting for 2026 | 2026-06-03 10:00 | -- | ||
| First quarter earnings conference call for 2026 | 2026-05-06 08:30 | -- | ||
| First quarter earnings results for 2026 | 2026-05-06 | -- | ||
| Fourth quarter earnings conference call for 2025 | 2026-03-05 08:30 | -- | ||
| Annual report for 2025 | 2026-03-05 | -- |
Show
Entries
Bioventus Inc Frequently Asked Questions
What is Bioventus Inc(FRA:4B8)'s stock price today?
The current price of FRA:4B8 is €11.95. The 52 week high of FRA:4B8 is €13.10 and 52 week low is €8.06.
When is next earnings date of Bioventus Inc(FRA:4B8)?
The next earnings date of Bioventus Inc(FRA:4B8) is 2026-11-04 Est..
Does Bioventus Inc(FRA:4B8) pay dividends? If so, how much?
Bioventus Inc(FRA:4B8) does not pay dividend.
Press Release
Articles on Bioventus Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers